![Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost‐effective - Armstrong - 2021 - Journal of the European Academy of Dermatology Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost‐effective - Armstrong - 2021 - Journal of the European Academy of Dermatology](https://onlinelibrary.wiley.com/cms/asset/4ad7768d-111a-4ce3-bd94-5c46e83e2eee/jdv.v35.s1.cover.jpg)
Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost‐effective - Armstrong - 2021 - Journal of the European Academy of Dermatology
![LEO PHARMA: Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment | FDA Health News LEO PHARMA: Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment | FDA Health News](https://s3.amazonaws.com/jnswire/jns-media/25/c8/11487464/img_26102020_085357_-1000_x_667_pixel.jpg)
LEO PHARMA: Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment | FDA Health News
![Full article: Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study Full article: Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study](https://www.tandfonline.com/cms/asset/f5d8c0e9-6b38-43a3-84c4-124484fdfedb/ijdt_a_1083935_f0005_b.jpg)
Full article: Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE SORILUX Foam is indicated for the topical treatment of plaque psoriasis of
![Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color - JDDonline - Journal of Drugs in Dermatology Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color - JDDonline - Journal of Drugs in Dermatology](https://s3.amazonaws.com/dl.jddonline.com/articleimages/M6910_ALEXIS/Efficacy-and-Safety-of-Calcipotriene-Betamethasone-Dipropionate-Foam-in-the-Treatment-of-Psoriasis-in-Skin-of-Color-FIGURE1.png)
Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color - JDDonline - Journal of Drugs in Dermatology
![Enstilar (calcipatriene and betamethasone dipropionate) Foam 0.0005%/0.064%, 60 g Leo Pharma (RX) Ingredients and Reviews Enstilar (calcipatriene and betamethasone dipropionate) Foam 0.0005%/0.064%, 60 g Leo Pharma (RX) Ingredients and Reviews](https://cdn1.skinsafeproducts.com/photo/B6338D035CC32D/large_1619041065.png?1619041065)
Enstilar (calcipatriene and betamethasone dipropionate) Foam 0.0005%/0.064%, 60 g Leo Pharma (RX) Ingredients and Reviews
![These highlights do not include all the information needed to use ENSTILAR Foam safely and effectively. See full prescribing information for ENSTILAR Foam. ENSTILAR® (calcipotriene and betamethasone dipropionate) foam, for topical use These highlights do not include all the information needed to use ENSTILAR Foam safely and effectively. See full prescribing information for ENSTILAR Foam. ENSTILAR® (calcipotriene and betamethasone dipropionate) foam, for topical use](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=enstilar-09.jpg&id=641339)
These highlights do not include all the information needed to use ENSTILAR Foam safely and effectively. See full prescribing information for ENSTILAR Foam. ENSTILAR® (calcipotriene and betamethasone dipropionate) foam, for topical use
![Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, 60g, LEO Pharma (RX) Ingredients and Reviews Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, 60g, LEO Pharma (RX) Ingredients and Reviews](https://cdn1.skinsafeproducts.com/photo/A3ADC29E44D315/large_1566239164.jpeg?1566239164)
Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, 60g, LEO Pharma (RX) Ingredients and Reviews
![The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes - JDDonline - Journal of Drugs in Dermatology The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes - JDDonline - Journal of Drugs in Dermatology](https://s3.amazonaws.com/dl.jddonline.com/articleimages/article_3621/Table-1.jpg)